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Abstract 
 
Background: In general, previous epidemiological studies evaluated congenital heart defects (CHDs) together. The aim of the present 
study was to identify possible etiological factors of different CHD-entities, because the underlying causes are unclear in the vast majority 
of patients.  
Objectives: Different CHD-entities as homogeneously as possible with confirmed diagnoses were analyzed in the population-based large 
dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities.  
Methods: 3,750 live-born singleton CHD-patients were analyzed according to birth outcomes, i.e. gestational age at delivery and birth 
weight, the rate of preterm birth, low birthweight and small for gestational age.  
Results: The major findings of the study showed that cases with different CHD-entities had shorter gestational age at delivery and lower 
mean birth weight, and these variables associated with a higher rate of preterm birth and particularly with a much higher rate of low 
birthweight and small for gestational age. This study showed the importance of sex in the birth outcomes of some CHD-entities. The 
question is why several CHD-entities manifested more frequently in newborns with intrauterine growth restriction because fetal heart has 
a passive role before birth without pulmonary circulation.  
Conclusions: The birth outcomes of cases indicate the effect of CHDs for fetal development. In addition maternal confounders have to 
consider. Finally, CHDs and intrauterine growth restriction as two developmental errors may have a common route, thus fetal growth and 
birthweight associated gene polymorphisms may have a role in the origin of CHDs. 
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1. Introduction 
The aim of our project is to reveal the possible environmental risk 
factors in the origin of CHDs in the population-based Hungarian 
Case-Control Surveillance of Congenital Abnormalities 
(HCCSCA) (Czeizel et al. 2001). However, CHDs cannot be 
regarded as a single homogeneous CA (Botto et al. 2007) 
therefore; CHD-entities/groups were separated according to the 
classification of CHDs used in the Baltimore-Washington Infant 
Study (Ferencz et al. 1993, Ferencz et al. 1997). In addition 
syndromic/multiple CAs including CHD were excluded from the 
study material and only the serious cases with confirmed diagnosis 
due to lethal outcome or catheter diagnosis or surgical correction 
were included in the study and CHD–entities were evaluated as 
homogeneous CHD-entities as possible. This approach needs the 
previous analysis of birth outcomes of patients with CHD, and 
these data are presented here based on the HCCSCA (Czeizel et al. 
2001). 
 
2. Methods 
2.1. The Hungarian Congenital Abnormality Registry 
(HCAR) 
The HCAR was established as the first national-based registry of 
CAs in the world, 1962 (Czeizel 1997, Czeizel et al. 2014). 
Reporting of patients as cases with CA to the HCAR is mandatory 
for physicians from the birth until the end of first postnatal year. 
Most cases are reported by obstetricians (in Hungary practically 
all deliveries occur in inpatient obstetric clinics and birth 
attendants are obstetricians) and pediatricians (who are working in 
the neonatal units of inpatient obstetric clinics and various, general 
and specialized, e.g. cardiologic inpatient and outpatient pediatric 
clinics). Autopsy is mandatory for all infant deaths and common 
(80%) in stillborn fetuses during the study period, and pathologists 
send a copy of the autopsy report to the HCAR if defects were 
identified. Since 1984, prenatal diagnostic centers were also asked 
to report malformed fetuses diagnosed prenatally with or without 
elective termination of pregnancy to the HCAR. 
In the HCAR cases with CAs are differentiated into isolated 
(including single, sequence and complex groups) and multiple or 
syndromic (including CA-syndromes, CA-associations and 
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unclassified multiple CAs) categories (Czeizel et al. 1993). The 
multimalformed cases had 2 or more CAs in different organs with 
or without minor anomalies. Thus the unit of recording was the 
person and not the CA in the HCAR. The recorded total (birth + 
fetal) prevalence rate of cases with CA was 35 per 1000 
informative offspring (live-born infants, stillborn fetuses and 
electively terminated malformed fetuses) between 1980 and 1996 
(Czeizel 1997) and about 90% of major CAs were recorded in the 
HCAR (Czeizel et al. 1993).  
2.2. The Hungarian Case-Control Surveillance of Con-
genital Abnormalities (HCCSCA) 
Cases with CA including CHD in the HCCSCA were selected 
from the HCAR. Only those CA cases were selected from the 
HCAR for the HCCSCA that were reported to the HCAR during 
the first three months after birth or elective termination of 
pregnancy. In addition cases with CA-syndromes caused by gene 
mutations or chromosomal aberrations with preconception origin 
were excluded. 
Population controls were defined as newborn infants without CAs 
and were selected from the National Birth Registry of the Central 
Statistical Office for the HCCSCA based on case lists for each 
quarter of the years from the HCAR. In general, two controls were 
matched to every case according to sex, birth week, and district of 
parents’ residence. If controls were twins, only one of them was 
randomly selected as controls for the HCCSCA.  
A letter with informed consent was mailed continuously to the 
address of the mothers of cases and controls immediately after 
their selection for the HCCSCA and requested that they send us 
the prenatal maternity logbook, discharge summary of their 
delivery and every medical record concerning their pregnancy and 
their child’s CA. These documents were sent back within four 
weeks.  
The mean + S.D. time elapsed between the end of pregnancy and 
return of the “information package” (including logbook, discharge 
summary, signed informed consent, etc.) in our prepaid envelope 
was 3.5 + 2.1 and 5.2 + 2.9 months in cases and population 
controls, respectively. 
In addition regional district nurses were asked to visit all non-
respondent case mothers and to evaluate the available medical 
documents. Unfortunately, district nurses could visit only 200 
non-respondent (Czeizel et al. 2003) and 600 respondent (Czeizel 
& Vargha 2004) control mothers in two validation studies because 
the ethics committee considered this follow-up to be disturbing for 
the parents of all healthy children.  
The necessary information was available for 96.3% of cases 
(84.4% from replies and 11.9% from visits) and 83.0% of 
population controls (81.3% from replies and 1.7% from visits). 
The signed informed consent was sent back by 98% of mothers. 
The name and address were deleted in 2% of subjects without 
signed informed consent. The flow of cases and population 
controls in the HCCSCA was reported previously (Ács et al. 2005). 
The data of sex and birth outcomes in cases were based on the 
Notification Form of Cases with CA in the HCAR confirmed by 
the discharge summary of delivery in the HCCSCA. The sex and 
birth outcomes of population controls were evaluated by the help 
of the discharge summary of delivery in the HCCSCA. The 
gestational age at delivery was calculated in a week from the first 
day of the last menstrual period while the definition of preterm 
birth (PTB) was as the time of birth of live-born babies in less 
than 37 completed gestation weeks. The rate of low birthweight 
(LBW) newborns (less than 2500 gram) was calculated based on 
birth weight, while the definition of small for gestational age 
(SGA) was birth weight less than 2500 g in newborn infants born 
on 37th gestational week or later.  
The method of data collection was changed in 1997 (since all case 
and control mothers are visited and questioned at home by 
regional nurses, but these data have not been validated at the time 
of this analysis), and it explains that here only the 17 years’ 
dataset of the HCCSCA, 1980-1996 are evaluated.  
2.3. Study design of cases with CHD 
The major evaluation problem of CHDs was that in general cases 
with CA were reported immediately after birth to the HCAR and 
about 50% of cases with CHD were reported as unspecified CHD, 
because the exact diagnosis of CHDs needed further time 
consuming examinations. The collection of medical data of cases 
with CA in the HCCSCA was 3.5 + 2.1 months later thus, we 
could get specified CHD diagnoses in further 20% of cases. The 
remaining 30% of CHD cases with unspecified diagnosis were 
expected to have been cared for or had surgical intervention in the 
pediatric cardiologic institutions in Hungary. Thus the staff of the 
HCCSCA visited the cardiologic in- and outpatient clinics in 2008 
and reviewed the medical records of patients. In cases with 
unspecified CHD, wherever possible, the diagnoses were modified 
to specific CHD. In addition, the previous diagnosis of CHD was 
checked and sometimes modified. If previously reported cases 
were not identified in the records of pediatric cardiologic 
institutions, we corresponded with mothers to clarify the fate 
and/or diagnosis of these cases in 2009 and 2010. However, if 
these mothers were not found or cases had further unspecified 
CHD, or mothers refused to collaborate, the cases were excluded 
from the study. 
There were three selection steps in the evaluation of cases with 
CHD: 
i) Cases with syndromic CHD due to major mutant genes (e.g. 
Holt-Oram) or chromosomal aberrations (e.g. Down) were 
excluded from the HCCSCA, and unclassified multiple CAs 
including CHD were also excluded from the study. 
ii) Cases with CHD were classified according to the system of 
The Baltimore-Washington Infant Study (Ferencz et al. 1993, 
Ferencz et al. 1997), including homogeneous structural 
entities/groups of CHD with a sufficient number of cases. 
iii) Some types of CHD have a wide spectrum of manifestations, 
including spontaneous closure of ventricular or atrial septal 
defects, ductus arteriosus, etc. Thus finally only cases with 
lethal outcomes verified by autopsy record or with 
documented catheter diagnoses or surgical corrections were 
included in the study. 
Our cases, therefore, represent homogeneous groups of severe 
manifestations of different entities of CHD.  
2.4. Statistical analysis 
The software GNU R 2.14, RStudio 0.97 version was used for the 
statistical analysis of data. At the evaluation of quantitative birth 
outcomes such as gestational age at delivery and birth weight of 
newborn infants, Student t-test was used. At the evaluation of 
categorical variables: PTB, LBW and SGA were analyzed by odds 
ratios (OR) with 95% confidence intervals (CI) in a multivariable 
unconditional regression model at the comparison of cases and 
population controls. At the calculation of adjusted OR, maternal 
age and birth order were considered. 
3. Results 
The number of cases with different CHD-entities/groups and their 
abbreviations are shown in Table 1. Of 22 CHDs, 17 were CHD-
entities, however. 4-4 entities were combined as CTD, RSOD and 
LSOD groups, respectively, and other rare CHDs were evaluated 
together in the group of OCHDs while other unspecified complex 
CHDs (e.g. VSD + ASD) in the group of CCHD. The birth 
outcomes of the latter two CHD-groups including heterogeneous 
CHDs will not be evaluated here in detail. 
Finally, 3,849 cases with confirmed diagnosis were evaluated, but 
15 occurred in stillborn fetuses. The sex (percentage proportion of 
boys) and twin rate (%) of different CHD-entities/groups were 
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analyzed in 3,834 live-born cases compared to the Hungarian 
newborns as reference (51.3%) in Table 1. The proportion of boys 
was 50.7%, while the rate of twin deliveries was 2.2% in the 
Hungarian newborns. The sex of cases with total CHD was near to 
the population reference figure, but their rate of twins was 2 fold 
higher. 
The evaluation of birth outcomes of cases with CHD was based on 
singletons because 84 twin cases had drastically shorter 
gestational age and smaller birth weight. Thus finally 3,750 
singleton live-born cases with different CHD-entities and groups 
were evaluated. Our population-based data set included 37,741 
singleton live-born population controls without CA, 1.8% of all 
live-births in Hungary and their birth outcomes corresponded well 
to the data of the Hungarian newborn population. Beyond sex of 
newborns, maternal age and birth order also have effect for birth 
outcomes. At the calculation of adjusted p value and OR, sex of 
cases and population controls, maternal age and birth order were 
considered (Table 2). 
 
 
Table 1: Number of Live-Births, Boys and Twins in Different Study Groups 
Study groups Abbreviation Total N 
Boys  Twins  
No. % No. % 
Hungarian newborns   2,134,150 1,094,017  51.3 1,088 1.1 
Ventricular septal defect* VSD 1,659 801 48.3 28 1.7 
Single ventricle SV 76 40 52.6 4 5.3 
Atrial septal defect secundum ASD-II 471 221 46.9 17 3.6 
Common atrioventricular canal CAVC 79 32 40.5 2 2.5 
Patent ductus arteriosus PDA 181 77 42.5 6 3.3 
 Common truncus  CT  44  31  70.5  1  2.3 
 Transposition of great arteries  TGA  307  169  55.0  5  1.6 
 Tetralogy of Fallot  TF  222  127  57.2  6  2.7 
 Double outlet of right ventricle  DORV  24  12  50.0  0  0.0 
Conotruncal defects CTD 597 339 56.8 12 2.0 
 Atresia/stenosis of pulmonary valve  A/SPV  72  37  51.4  0  0.0 
 Atresia/stenosis of tricuspid valve  A/STV  13  5  38.5  0  0.0 
 Ebstein’s anomaly  EA  7  6  85.7  0  0.0 
 CAs of pulmonary artery  CAPA  108  60  55.6  1  0.9 
Right sided obstructive defects RSOD 200 108 54.0 1 0.5 
 Valvular aortic stenosis  VAS  56  37  66.1  0  0.0 
 Hypoplastic left heart  HLH  76  49  64.6  3  3.9 
 Coarctation of aorta  COA  113  71  62.8  1  0.9 
 Other CAs of aorta  OCAA  57  38  66.7  3  5.3 
Left sided obstructive defects LSOD 302 195 64.6 7 2.3 
Other isolated CHD OCHD 186 86 46.2 5 2.7 
Other complex CHD CCHD 83 44 53.0 2 0.2 
Total CHD 3,834 1943 50.7 84 2.2 
*perimembranous and muscular ventricular septal defects 
 
Table 2: Mean Maternal Age and Birth Order in Groups of Singleton Live-Born Cases with Different CHD Groups/Entities and Population Controls (PC) in the HCCSCA. 
Study groups                             Total 
N 
Maternal age 
Mean     S.D. 
Birth order 
Mean      S.D. 
PC 37,741 25.4         4.9 1.7          0.9 
VSD 1,631 25.6         5.2 1.9          1.2 
SV 72 25.9         5.7 1.9          1.0 
ASD-II 454 26.0         5.8 2.1          1.3 
CAVC 77 26.4         5.4 2.1          1.3 
PDA 175 25.7         5.2   2.0          1.4  
      CT 43 25.1         4.2 2.0          1.2 
      TGA 302 26.0         5.0 1.9          1.2 
      TF 216 25.2         5.3 1.8          1.0 
      DORV 24 26.6         4.3 2.0          0.8 
CTD 585 25.7         5.1 1.9          1.1 
      A/SPV 72 25.8         5.2 1.9          1.2 
      A/STV 13 25.0         4.1 1.7          1.0 
      EA 7 24.3         7.6 1.6          1.1 
      CAPA 107 26.3         5.9   2.1          1.3  
RSOD 199 26.0         5.6 2.0          1.2 
      VAS 56 24.8         4.5 1.9          1.1 
      HLH 73 25.9         5.4 1.8          1.0 
      COA 112 25.9         5.6 2.0          1.0 
      OCAA 54 26.4         6.1 1.9          0.9 
LSOD 295 25.8         5.4 1.9          1.0 
OCHD 181 26.1         5.7 2.0          1.3 
CCHD 81 25.9         5.3 1.8          1.0 
 
Mean gestational age and birth weight of cases with different 
CHD entities/groups were compared to population controls, and 
differences were expressed in p values (Table 3). Cases with EA 
are not evaluated due to their limited number, thus the birth 
outcomes of 16 CHD-entities are analyzed. 
The first impression is that the severity of CHD-entities did not 
correlate with the shorter mean gestational age: there is no 
difference in mean gestational age between severe TGA, DORV, 
SV, TF and population controls, while the shortest gestational age 
was observed in cases with A/STV, ASD-II, OCAA, and PDA. 
All 16 CHD-entities had lower mean birth weight than population 
controls; the difference did not reach the level of significance only 
in cases with DORV. The shortest gestational age associated with 
a lower mean birth weight in cases with A/STV, PDA, ASD-II, 
and OCAA. The largest mean birth weight was recorded in the 
groups of TGA and DORV. Another impression is that the well-
known relation between gestational age and birth weight is not 
obvious in some CHD-entities. For example, the combined mean 
gestational age was 39.4 wk in the group of cases with CTD, 
similar to the figure of population controls, nevertheless their 
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mean birth weight was lower nearly 200 g due to mainly CT and 
TF. 
Mean gestational age and birth weight were evaluated in male and 
female singletons separately as well (Table 3). In the population 
control group, the mean gestational age was 0.1 wk shorter while 
the mean birth weight was 137 g smaller in males than in females. 
In general mean gestational age was shorter and mean birth weight 
was lower in both sexes of cases than in population controls. 
However, there were four exceptions (i) there was a longer 
gestational age in both male and female cases with TGA, (ii) mean 
gestational age was longer in female cases with DORV than in 
population controls, (iii) the mean birth weight was larger in male 
cases with DORV and (iv) mean birth weight was similar in males 
with A/SPV to the mean birth weight in the male population 
controls. The mean birth weight of female cases was smaller than 
in population controls in all CHD-entities/groups. 
Table 4 summarized the figures of categorical birth outcomes, i.e. 
rate of PTB, LBW and SGA in cases with different CHD-
entities/groups compared with the figures of population controls, 
and the differences are expressed in OR with 95% CI. Of 16 
CHD-entities, 6 (PDA, ASD-II, CAVC. HLH, CAPA and VSD) 
had higher rate of PTB. Of 16 CHD-entities, 14 showed higher 
rate of LBW but the two exceptional (DORV and VAS) had also 
higher rate of LBW, but the difference did not reach the level of 
significance though was near to it. The rate of SGA was also 
higher in most CHD-entities. Only four LSOD-entities were 
exceptional. 
In the next step, categorical birth outcomes of cases were 
differentiated according to sex (Table 5 and 6). ASD-II and PDA 
showed a higher rate of PTB in both sexes, while it occurred only 
in females with CAVC. The higher rate of LBW was observed in 
most CHD-entities of both sexes, particularly in male cases. Only 
VAS was exceptional in both sexes, in addition TGA, DORV and 
A/SPV in males, SV. A/STV, COA and OCAA in females did not 
show a significantly higher rate of LBW. The rate of SGA was 
also higher in most CHD-entities, except in male cases with 
DORV, A/SPV and three entities of LSOD: VAS, HLH, COA and 
female cases with SV, CAVC, A/STV and four entities of LSOD. 
The rate of PTB was higher in male cases while LWB and SGA 
were higher in females. In cases with VSD, ASD-II, RSOG and 
LSOD groups, the rate of PTB, LBW and SGA was higher in 
females than in males. The rate of LBW and SGA was higher in 
female cases with PDA and CTD group, but the rate of PTB was 
higher in males. 
 
 
Table 3: Number of Singletons, in Addition Male and Female Singletons and Their Mean Gestational Age at Delivery and Mean Birth Weight in Different Study Groups and 
Population Controls (PC) As Reference (R) 
Study Groups Total N Gestational age 
Mean   S.D.  p= 
Birth weight 
Mean  S.D.   p= 
Male gestational age 
N      Mean S.D.   p= 
Male birth weight 
Mean   S.D.    p= 
Female gestational age 
N       Mean  S.D. p= 
Female birth weight 
Mean    S.D.   p= 
PC 37,741 39.4    2.0   R 3,282  506      R 24,536 39.4  2.0   R 3,330   508     R 13,205  39.3 2.1   R 3,193    489    R 
VSD 1,631 39.1    2.3   0.000 3,059  590   0.000 784    39.2   2.3  0.001 3,141   608     0.000 847     39.1  2.3   0.187 2,983    564    0.000 
SV 72 39.3    2.4   0.918 3,090  549   0.003 38      39.0   2.4  0.246 3,136   590     0.027 34       39.6  2.4   0.252 3,038    504    0.117 
ASD-II 454 38.2    3.1   0.000 2,870  737   0.000 218    38.3   2.9  0.000 2,986   699     0.000 236     38.1  3.3   0.000 2,762    757    0.000 
CAVC 77 38.7    2.5   0.006 3,024  635   0.000 31      39.1   2.2  0.530 3,176   666     0.102 46       38.4  2.6   0.006 2,922    599    0.000 
PDA 175 38.3    3.2   0.000 2,701  764   0.000 74      37.9   3.4  0.000 2,724   789     0.000 101     38.6  3.0   0.004 2,685    749    0.000 
      CT 43 38.5    3.3   0.012 2,876  738   0.000 30      38.9   3.2  0.299 2,962   772     0.000 13       37.5  3.5   0.003 2,678    634    0.000 
      TGA 302 39.5    1.9   0.115 3,160  584   0.000 166    39.6   2.0  0.303 3,264   588     0.097 136     39.5  1.8   0.160 3,033    556    0.000 
      TF 216 39.3    1.9   0.882 3,009  532   0.000 123    39.3   1.9  0.836 3,067   570     0.000 93       39.3  1.8   0.915 2,931    470    0.000 
      DORV 24 39.4    2.0   0.913 3,171  563   0.301 12      39.3   1.6  0.825 3,409   426     0.587 12       39.5  2.4   0.665 2,933    597    0.073 
CTD 585 39.4    2.0   0.699 3,083  583   0.000 331    39.4   2.1  0.802 3,169   605     0.000 254     39.3  2.0   0.609 2,973    536    0.000 
      A/SPV 72 39.3    2.4   0.987 3,094  706   0.007    37      39.6   2.2  0.398 3,334   578     0.596 35       38.9  2.6   0.477 2,841    746    0.000 
      A/STV 13 37.3    3.7   0.000 2,616  899   0.000 5        36.0   5.2  0.000 2,450   1,416  0.000 8         38.1  2.5   0.166 2,720    455    0.011 
      EA 7 38.3    3.1   0.139 2,700  609   0.002 6        38.2   3.4  0.111 2,725   663     0.004 1         39.0  0.0   0.801 2,550    0        0.154 
      CAPA 107 38.9    2.7   0.039 3,009  716   0.000 60      38.9   2.4  0.075 3,039   660     0.000 47       38.9  3.1   0.308 2,972    787    0.003 
RSOD 199 38.9    2.7   0.006 3,003  727   0.000 108    39.0   2.6  0.038 3,095   705     0.000 91       38.8  2.9   0.107 2,895    743    0.000 
      VAS 56 39.1    2.4   0.545  3,038  529   0.001 37      39.0   2.1  0.284 3,051   516     0.002 19       39.4  3.0   0.635 3,013    566    0.184 
      HLH 73 38.7    2.9   0.004 2,960  644   0.000 47      38.7   3.0  0.018 3,000   659     0.000 26       38.6  2.6   0.108 2,888    622    0.002 
      COA 112 38.9    2.6   0.035 3,083  615   0.000 71      38.8   2.6  0.018 3,120   651     0.001 41       39.1  2.6   0.715 3,018    548    0.034 
      OCAA 54 38.3    2.7   0.001 2,997  692   0.000 37      38.4   2.3  0.004 3,008   646     0.000 17       38.2  3.5   0.066 2,973    805    0.153 
LSOD 295 38.8    2.6   0.000 3,028  621   0.000 192    38.7   2.6  0.000 3,056   626     0.000 103     38.9  2.8   0.118 2,977    611    0.000 
OCHD 181 38.2    3.0   0.000 2,828  731   0.000 83      38.4   2.9  0.000 2,963   703     0.000 98       38.0  3.0   0.000 2,714    739    0.000 
CCHD  81 39.1    2.4   0.305 3,053  603   0.000 42      38.5   2.6  0.003 3,045   662     0.000  39       39.6  2.0   0.095 3,062    540    0.114 
Total 3,750 38.9    2.5   0.000 3,007  643   0.000 1,901 38.9   2.5  0.000 3.092   646     0.000 1,849  38.6  2.6   0.000 2,920    629    0.000 
 
Table 4: Number of Singletons, and Rates of Their Preterm Birth (PTB), Low Birthweight (LBW) and Small for Gestational Age (SGA) in Different Study Groups and Popula-
tion Controls (PC) As Reference 
Study groups Total 
N 
Preterm birth (PTB) Low birthweight (LBW) Small for gestational age (SGA) 
No.     %     OR,     95% CI No.       %     OR,     95% CI No.     %     OR,     95% CI 
PC 37,754 3,385  9.0 Reference 2,023   5.4 Reference 816    2.2 Reference 
VSD 1,631 192   11.8 1.24,   1.06-1.44 257     15.8 2.98,   2.58-3.43 146    9.0 4.06,   3.36-4.87 
SV 72 8       11.1 1.13,   0.50-2.24 12       16.7 3.10,   1.57-5.63 5        6.9 3.01,   1.05-6.81 
ASD-II 454 100   22.0 2.60,   2.05-3.25 120     26.4 5.50,   4.40-6.84 37      8.1 3.49,   2.42-4.88 
CAVC 75 15     19.5 2.20,   1.04-3.79 16       20.8 4.00,   2.20-6.87 9       12.0 5.44,   2.51-10.44 
PDA 175 42     24.0 2.85,   1.98-4.02 66       37.7 9.55,   6.92-13.08 34     19.4 9.73,   6.51-14.15 
      CT 43 8       18.6 2.02    0.86-4.18 15       34.9 8.62,   4.41-16.18 10     23.3 12.92, 5.97-25.63 
      TGA 302 23     7.6 0.79,   0.50-1.19 33       10.9 2.02,   1.37-2.87 26     8.6 4.04,   2.62-5.97 
      TF 216 14     6.5 0.66,   0.36-1.09       30       13.9 2.68,   1.77-3.91 24     11.1 5.33,   3.37-8.06 
      DORV 24 2       8.3 0.86,   0.14-2.96 4         16.7 3.26,   0.93-8.79 4       16.7 8.76,   2.52-23.55 
CTD 585 47     8.0  0.83,   0.60-1.11 82       14.0 2.69,   2.10-3.40 64     10.9 5.27,   3.98-6.86 
      A/SPV 72 11     15.3 1.60,   0.79-2.94 13       18.1 3.21,   1.66-5.74 8       11.1 4.72,   2.07-9.39 
      A/STV 13 2       15.4 1.80,   0.28-6.84 5         38.5 11.77, 3.43-36.5 4       30.8 20.71, 5.47-65.50 
      EA 7 1       14.3 1.72,   0.09-10.39 2         28.6 7.84,   1.09-37.77 1       14.3 8.05,   0.42-48.22 
      CAPA 107 18     16.8 1.93,   1.12-3.15 26       24.3 4.86,   3.03-7.56 13     12.1 5.17,   2.72-9.03 
RSOD 199 32     16.1 1.80,   1.20-2.60 46       23.1 4.61,   3.24-6.43 26     13.1 5.79,   3.70-8.69 
      VAS 56 5       8.9 0.88,   0.30-2.02 7         12.5 2.17,   0.89-4.56 3       5.4 2.22,   0.54-6.10 
      HLH 73 13     17.8 2.13,   1.11-3.78 11       15.1 3.02,   1.49-5.57 2       2.7 1.21,   0.20-3.89 
      COA 112 13     11.6 1.27,   0.67-2.19 14       12.5 2.32,   1.26-3.95 5       4.5 1.89,   0.67-4.22 
      OCAA 54 8       14.8 1.49,   0.65-3.01 12       22.2 4.04,   2.01-7.55 4       7.4 2.91,   0.87-7.20 
LSOD 295 39     13.2 1.42,   1.00-1.98 44       14.9 2.77,   1.97-3.80 14     4.7 1.99,   1.10-3.31 
OCHD                                          181       44     24.3         3.02,   2.12-4.25              52       28.7      6.25,   4.43-8.68          19     10.5        4.51,   2.68-7.17 
CCHD                                            81         9       11.1         1.25,   0.58-2.37              11       13.6      2.66,   1.32-4.86            6       7.4        3.40,   1.31-7.26 
Total                                         3,750 528   14.1         1.51,   1.36-1.67            706     18.8      3.68,   3.34-4.04        360   9.6       4.39,   3.85-5.00 
Bold numbers show significant associations 
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Table 5: Number of Male Singletons, and Rates of Their Preterm Birth (PTB), Low Birthweight (LBW) and Small for Gestational Age (SGA) in Different Study Groups and 
Population Controls (PC) As Reference 
Study groups Total 
N 
Preterm birth (PTB) Low birthweight (LBW) Small for gestational age (SGA) 
No.     %     OR,     95% CI No.     %     OR,     95% CI No.     %     OR,     95% CI 
PC 25,540 1,996  8.1 Reference 1,155  4.7 Reference 432     1.8 Reference 
VSD 784 83      10.6 1.25,   0.98-1.57 117     14.9 3.29,   2.66-4.03 73       9.3 5.39,   4.12-6.95 
SV 38 5        13.2 1.52,   0.52-3.60 7         18.4 4.05,   1.61-8.87 3         7.9 4.38,   1.05-12.35 
ASD-II 218 39      17.9 2.23,   1.54-3.14 45       20.6 4.50,   3.16-6.29 15       6.9 3.61,   2.02-6.00 
CAVC 31 4        12.9 1.53,   0.45-3.95 6         19.4 4.30,   1.57-9.99 5         16.1 9.84,   3.29-23.98 
PDA 74 20      27.0 3.85,   2.23-6.39 27       36.5 10.86, 6.59-17.57 11       14.9 9.18,   4.53-16.95 
      CT 30 4        13.3 1.41,   0.41-3.67 11       36.7 10.19, 4.58-21.60 8         26.7 18.80, 7.74-41.29 
      TGA 166 16      9.6 1.15,   0.65-1.87 14       8.4 1.74,   0.95-2.92 9         5.4 3.09,   1.45-5.76 
      TF 123 9        7.3 0.81,   0.38-1.52 18       14.6 3.22,   1.87-5.24 14       11.4 6.61,   3.58-11.31 
      DORV 12 1        8.3 0.84,   0.05-4.93 0         00.0 0.00,   0.00-1.21 0         0.0 0.00,   0.00-1638.50 
CTD 331 30      9.1 1.04,   0.69-1.49 43       13.0 2.78,   1.97-3.82 31       9.4 5.43,   3.63-7.86 
      A/SPV 37 5        13.5 1.56,   0.53-3.71 3         8.1 1.50,   0.36-4.24 1         2.7 1.29,   0.07-6.05 
      A/STV 5 1        20.0 3.56,   0.18-24.27 3         60.0 44.91, 7.34-344.8 2         40.0 47.13, 6.14-288.44 
      EA 6 1        16.7 2.18,   0.11-14.02 2         33.3 11.52, 1.54-61.26 1         16.7 12.86, 0.66-81.52 
      CAPA 60 9        15.0 1.91,   0.87-3.72 13       21.7 4.87,   2.49-8.89 7         11.7 5.80,   2.35-12.24 
RSOD 108 16      14.8 1.86,   1.04-3.09 21       19.4 4.39,   2.62-7.02 11       10.2 5.30,   2.63-9.64 
      VAS 37 3        8.1 0.87,   0.21-2.45 4         10.8 2.11,   0.62-5.40 2         5.4 2.80,   0.45-9.35 
      HLH 47 7       14.9 1.93,   0.78-4.08 6         12.8 2.91,   1.10-6.42 1         2.1 1.16,   0.07-5.36 
      COA 71 9       12.7 1.60,   0.74-3.08 9         12.7 2.70,   1.24-5.22 2         2.8 1.39,   0.23-4.47 
      OCAA 37 5       13.5 1.54,   0.52-3.65 8         21.6 4.82,   2.03-10.21 2         5.4 4.26,   1.02-11.99 
LSOD 192 24     12.5 1.51,   0.95-2.28 27       14.1 3.02,   1.95-4.51 8         4.2 2.16,   0.97-4.16 
OCHD                                          83    19     22.9         3.1,     1.79-5.12              18       21.7      4.88,   2.76-8.20                  5         6.0        3.04,   1.06-6.89 
CCHD                                            42                   7       16.7         2.3,     0.93-4.91              7         16.7      3.90,   1.57-8.39                  4         9.5        5.36,   1.59-13.56 
Total                                         1,901 247   13.0         1.55,   1.34-1.79            318     16.7      3.69,   3.22-4.23             166     8.7       4.93,   4.07-5.94 
Bold numbers show significant associations 
 
Table 6: Number of Female Singletons, and Rates of Their Preterm Birth (PTB), Low Birthweight (LBW) and Small for Gestational Age (SGA) in Different Study Groups and 
Population Controls (PC) As Reference 
Study groups Total N Preterm birth (PTB) Low birthweight (LBW) Small for gestational age (SGA) 
No.         %.            OR,  95% CI No.        %       OR,   95% CI             No.        %       OR,     95% CI 
PC 13,214 1,389    10.5 Reference 864      6.5         Reference 384       2.9        Reference 
VSD 847 109       12.9  1.13, 0.91-1.38 140      16.5    2.46,  2.01-2.99 73         8.6    2.80,    2.14-3.63 
SV 34 3           8.8 0.74, 0.18-2.10 5          14.7    2.11,  0.71-5.11 2           5.9    1.81,    0.29-6.06 
ASD-II 236 61         25.8 2.37, 1.96-3.59 75        31.8    5.71,  4.24-7.63 22         9.3    2.92,    1.80-4.52 
CAVC 46 11         23.9 2.40, 1.15-4.63 10        21.7    3.42,  1.58-6.80 4           8.7    2.86,    0.85-7.21 
PDA 101 22         21.8 2.06, 1.24-3.28 39        38.6    7.60,  4.95-11.52 23         22.8    8.29,    4.99-13.27 
      CT 13 4           30.8 3.77, 1.01-11.70 4          30.8    7.34,  1.94-23.32 2           15.4    7.04,    1.06-27.55 
      TGA 136 7           5.1 0.43, 0.18-0.86 19        14.0    2.13,  1.26-3.44 17         12.5    4.47,    2.55-7.36 
      TF 93 5           5.4 0.47, 0.17-1.05 12        12.9    2.09,  1.07-3.73 10         10.8    4.01,    1.92-7.49 
       DORV 12 1           8.3 0.73, 0.04-3.81 4          33.3    7.66,  1.97-25.58 4           33.3    18.67,  4.78-63.42 
CTD 254 17         6.7 0.58, 0.34-0.92 39        15.4    2.50,  1.73-3.52 33         13.0    4.88,    3.27-7.08 
      A/SPV 35 6           17.1 1.51, 0.56-3.45 10        28.6    4.69,  2.09-9.74 7           20.0    7.15,    2.82-15.84 
      A/STV 8 1           12.5 1.02, 0.05-5.94 2          25.0    3.81,  0.53-17.63 2           25.0    9.52,    1.34-43.88 
      EA 1 0           0.0 0.00, 0.00- inf 0          0.0    0.00,  0.00-inf 0           0.0    0.00,    0.00-Inf 
      CAPA 47 9           19.1 1.88, 0.85-3.76 13        27.7    4.76,  2.37-9.03 6           12.8    4.41,    1.65-9.88 
RSOD 91 16         17.6 1.64, 0.91-2.76 25        27.5    4.60,  2.80-7.35 15         16.5    5.84,    3.17-10.09 
      VAS 19 2           10.5 0.89, 0.14-3.14 3         15.8    2.38,  0.54-7.47 1           5.3    1.68,    0.09-8.44 
      HLH 26 6           23.1 2.45, 0.89-5.84 5         19.2    3.12,  1.02-7.89 1           3.8    1.22,    0.07-5.87 
      COA 41 4           9.8 0.83, 0.25-2.09 5         12.2    1.83,  0.62-4.32 3           7.3    2.46,    0.59-6.93 
      OCAA 17 3           17.6 1.44, 0.33-4.50 4         23.5    3.07,  0.84-9.03 1           5.9    1.47,    0.08-7.43 
LSOD 103 15         14.6 1.30, 0.72-2.19 17       16.5    2.45,  1.39-4.08 6           5.8    1.81,    0.70-3.86 
OCHD                               98 25         25.5           2.74, 1.69-4.31              34       34.7    6.62,  4.23-10.19             14         14.3    4.61,    2.45-8.06 
CCHD                               39 2           5.1           0.43, 0.07-1.43                4         10.3    1.54,  0.46-3.92                 2           5.1    1.71,    0.28-5.67 
Total                             1,849 281       15.2           1.37, 1.19-1.58            388     21.0    3.34,  2.92-3.83             194       10.5    3.53,    2.94-4.24 
Bold numbers show significant associations 
4. Discussion 
The major findings of the study suggested that in general cases 
with different CHD-entities had a shorter gestational age at 
delivery and lower mean birth weight, and these variables 
associated with a higher rate of PTB and particularly with a much 
higher rate of LBW and SGA.  
Three CHD-entities and/or groups are worth more discussion.  
i) Cases with ASD-II had localized small defect of an atrial 
septum (Fyler 1992, Vereczkey et al. 2013), nevertheless, their 
mean gestational age was 1.2 wk shorter and their mean birth 
weight was 412 g smaller than population controls. The rate of 
PTB, LBW and SGA was 2.4. 4.9 and 3.7 fold higher in cases 
with ASD-II than in population controls, respectively. Thus 
intrauterine growth restriction was characteristic for ASD-II, 
mainly in female cases. There was no robust difference in the 
mean gestational age of males and females (1.1 vs. 1.2 wk), 
but the mean birth weight (431 g) was smaller in females than 
in males (314 g). The rate of PTB (2.5 vs. 2.2 fold) and LBW 
(4.9 vs. 4.4 fold) was higher in female cases that in male cases 
compared to their appropriate sex controls. However, this 
difference was reverse in the rate of SGA (3.2 vs. 3.8 fold). 
ii) TGA is severe CHD-entity, nevertheless, newborns with TGA 
had somewhat longer gestational age (0.1 wk), but mean birth 
weight was 66 and 160 g smaller in male and female cases 
than in male and female controls, respectively. There was no 
higher rate of PTB in male and female cases, LBW rate was 
higher only in female cases. However, SGA showed a higher 
rate in both sexes. Thus TGA had no effect for the gestational 
age and PTB, but TGA was associated with intrauterine 
growth restriction, mainly in female cases. 
iii) In general, the four types of LSOD had no higher rate of PTB 
in male and female cases, and only HLH had a higher rate of 
LBW in both sexes. In addition, the rate of LBW was higher 
in males with COA and OCAA, while higher rate of SGA 
occurred only in male cases with OCAA. Thus intrauterine 
growth restriction occurred mainly in males. 
The birth prevalence of CHDs was 7.06 + 0.91 per 1000 in 
Budapest, 1963-1965 based on the HCAR completed with active 
search of records in all pediatric and pathologic institutions 
(Czeizel et al. 1972). However, the birth prevalence of CHDs was 
10.2 + 2.1 per 1000 in a Hungarian population-based study of a 
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country region, when each individual child was examined 
personally by a pediatric cardiologist in 1971-1972 or the autopsy 
report was evaluated in dead children (Mészáros et al. 1975). Thus 
the Hungarian rate of CHDs corresponded to the internationally 
reported figures (Hoffman et al. 2004, Reller et al. 2008, Dolk et 
al. 2011). In general, the sex of cases with different CHD-entities 
was also similar in our material than in other studies (Ferencz et al. 
1993, Reller et al. 2008). However, our study showed the 
importance of sex in the birth outcomes of some CHD-entities. 
The birth outcomes of cases with different CHD-entities/groups 
were presented in The Baltimore-Washington Infant Study 1981-
1989 (Ferencz et al. 1997). For example, mean gestational age and 
mean birth weight was 38.1 ± 0.3 wk and 2,939 ± 60 g in cases 
with ASD-II while these figures were 38.2 ± 3.1 wk and 2.870 ± 
737 g in our material, but the mean gestational age and birth 
weight of controls was 39.6 ± 0.1 wk and 3,351 ± 10 in The 
Baltimore-Washington Infant Study. The OR (95% CI) for SGA 
was 2.7 (1.7-4.1) in The Baltimore-Washington Infant Study [13] 
and 3.5 (2.4-4.9) in our material, respectively.  
TGA was also not associated with a higher rate of PTB in The 
Baltimore-Washington Infant Study (Ferencz et al. 1997) as in our 
study, and the birth outcomes of cases with LSOG group were 
also similar in the two study material. 
Only mean gestational age and birth weight were published in 
Metropolitan Atlanta Congenital Defects Program (Reller et al. 
2008). The mean gestational age was 38.0 wk in cases with PDA 
similar to 38.3 wk in our material. However, there was some 
difference in the mean gestational age (38.5 vs. 39.5 wk) of cases 
with TGA in there and our material though the difference in mean 
birth weight was small (3,173 vs. 3,160 g).  
Some difference in the birth outcomes of cases with different 
CHD-entities may be connected with the different ascertainment 
and selection of cases in different studies. We evaluated the severe 
cases with lethal outcome or after catheter diagnoses or surgical 
correction, thus or cases represented the tip of an iceberg. Thus the 
difference in birth outcomes of cases with different severe CHD-
entities suggests the different pathogenesis of CHD-entities. 
The question is why several CHD-entities are manifesting more 
frequently in newborns with PTB and mainly with LBW/SGA, 
because intrauterine growth restriction was observed in most 
CHD-entities. Three options are worth discussing. 
i) It is difficult to believe that a localized CA in the heart such as 
ASD-II can induce intrauterine fetal growth restriction 
because the fetal heart has a passive role before birth without 
pulmonary circulation. Nevertheless, our data indicate the 
effect of a fetal heart defects for fetal development. First 
Rosenthal (Rosenthal 1996) suggested that intrauterine life 
hemodynamic alterations due to the CHD may affect size and 
growth pattern of fetuses. 
ii) Possible confounding factors such as maternal age, birth order 
and socioeconomic status have to evaluate as well. Maternal 
age and birth order were considered for the calculation of 
adjusted p and OR values in this study. The poor 
socioeconomic status is associated with lower birth weight in 
general and e.g. in cases with VSD (Vereczkey et al. 2012). 
However, this effect cannot explain the differences among 
CHD-entities/groups. Drinking and mainly smoking habits are 
also important. However, our studies showed a similar rate of 
these lifestyle factors in the mothers of cases with CHD, thus 
these adverse lifestyle factors cannot explain totally the 
difference in fetal growth restriction of fetuses (Czeizel et al. 
2003). Maternal diseases and related drug treatments were also 
analyzed without any association with higher risk of 
intrauterine growth restriction of cases with CHD (Ács et al. 
2010). 
iii) CHDs and intrauterine growth restriction as two 
developmental errors may have a common route. Recently, the 
association of some gene polymorphisms with fetal growth 
and birth weight was shown (Freathy et al. 2010), thus it 
would be interesting to test the effect of these gene variants in 
the origin of CHDs. 
The strengths of our study are connected with the large 
population-based data set of the HCCSCA, including 3,750 
singleton live-born cases with CHD and 37,741 singleton live-
born population controls without CAs in the ethnically 
homogeneous Hungarian (Caucasian) population. Cases with 
CHD were reported by medical doctors and reported diagnoses 
were critically checked in the HCAR (Czeizel 1997, Czeizel et al. 
2014). In addition, the validity of CHD-diagnoses has been 
improved due to the available medical records on 3.5 + 2.1 months 
after the birth in the data set of the HCCSCA (Czeizel et al. 2001) 
and finally due to the follow-up of our cases in cardiologic 
institutes. We did our best to work with cases with CHD-entities 
as homogeneous as possible; therefore, cases with 
syndromic/multiple CA including CHD were excluded and finally 
only cases after catheter diagnosis or surgical correction or lethal 
outcome based on medical documents were planned to evaluate in 
the study. The data of birth outcomes were medically recorded.  
However, there were some weaknesses of our study. (i) The 
diagnosis of CHDs was accomplished during the study period 
(1980-1996), i.e. mainly before the spectacular improvement of 
medical technology, particularly echocardiography. However, our 
cases with CHD were selected until the end of third postnatal 
month and mainly surgically corrected or lethal cases were 
included in the study, thus mainly more severe CHDs cases were 
evaluated. (ii) Another weakness of our study is the lack of data 
regarding smoking and drinking habit in the total material of 
mothers of cases and controls. Our previous validation study 
showed the low reliability of retrospective self-reported 
information on these habits in control mothers and mainly in case 
mothers (Czeizel et al. 2003). Thus only the family consensus data 
after the home visit in a subsample of cases and controls were 
evaluated; therefore, we cannot consider the smoking and drinking 
habit as confounder in the mothers of all cases and controls.  
In conclusion, our findings showed significant difference in the 
birth outcomes of cases with CHD compared to their population 
controls. The higher rate of LBW and SGA indicates intrauterine 
fetal growth restriction in several CHD-entities and the sex of 
cases has some effect for their fetal development. The intrauterine 
growth restriction as a general developmental process may have 
some role in the origin of some CHD-entities. Nevertheless, birth 
outcomes of different CHD-entities were different and these 
findings confirmed the different pathogenesis of CHD-entities. 
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